心脏亚结构放疗剂量可预测肺癌放疗中高敏肌钙蛋白T升高
该研究基于160例回顾性队列和57例前瞻性队列的非小细胞肺癌患者,比较全心与心脏亚结构DVH参数及组学特征对放疗后hs-cTnT升高的预测能力。结果显示亚结构DVH模型交叉验证平均AUROC为0.71(95%CI 0.70-0.73),前瞻性验证AUROC为0.60,优于全心模型,左前降支V20Gy为最主要预测因子。
要点
- 心脏亚结构DVH模型预测hs-cTnT升高的性能优于全心模型。
- 左前降支V20Gy是最主要预测因子,不同指数下cutoff为0.2%–5%。
- 建议采用心脏亚结构进行心脏毒性风险评估。
核心结论
- 心脏亚结构DVH参数对NSCLC放疗中hs-cTnT升高的预测能力和稳健性优于全心变量。
研究设计与样本
- 回顾性队列纳入160例来自已完成前瞻性试验的NSCLC患者,前瞻性队列纳入57例正在进行的试验中的NSCLC患者。
- 使用自研自动分割模型勾画19个心脏亚结构,提取DVH参数及影像组学/剂量组学特征。
- 在回顾性队列中进行100次蒙特卡洛交叉验证(75%/25%分割),以前瞻性队列进行留出验证,以AUROC评估模型性能。
主要发现
- hs-cTnT升高发生率在回顾性队列为31.9%,前瞻性队列为29.8%。
- 亚结构DVH模型交叉验证平均AUROC为0.71(95%CI 0.70-0.73),前瞻性留出验证AUROC为0.60,全心模型前瞻性验证AUROC≤0.51。
- 特征分析显示左前降支V20Gy是最主要预测因子,不同指数下cutoff值为0.2%至5%。
关键数值与推荐
- hs-cTnT升高定义为较基线增加≥5 ng/L。
- 亚结构DVH模型交叉验证平均AUROC 0.71(95%CI 0.70-0.73)。
- 前瞻性留出验证中亚结构DVH模型AUROC为0.60,全心模型≤0.51。
- 左前降支V20Gy为最主要预测因子,cutoff值0.2%–5%。
临床怎么用
- 在肺癌放疗计划评估中可考虑勾画心脏亚结构并关注左前降支V20Gy等DVH参数。
- 心脏亚结构DVH参数可用于辅助评估hs-cTnT升高风险,指导心脏毒性风险分层。
局限性
- 回顾性队列存在选择偏倚可能,虽采用交叉验证减轻随机分割偏倚。
- 前瞻性验证队列样本量57例,模型稳健性仍需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cardiotoxicity is a major concern for patients undergoing thoracic radiation therapy. This study compared the predictive power of radiation dose-volume histogram (DVH) parameters and radiomic/dosiomic features of the whole heart (WH) and cardiac substructures for elevated circulating high-sensitivity cardiac troponin T (hs-cTnT), a biomarker for early detection of cardiac adverse events. METHODS AND MATERIALS: A retrospective cohort of 160 patients with non-small cell lung cancer (NSCLC) from a completed prospective trial and a prospective cohort of 57 patients with NSCLC enrolled in an ongoing trial were analyzed. The endpoint was hs-cTnT elevation, indicated by an increase of ≥5 ng/L from baseline. An in-house auto-segmentation model delineated 19 cardiac substructures. DVH parameters, radiomic, and dosiomic features were extracted from each patient. A 100-iteration Monte Carlo cross-validation (75%/25% split) was conducted within the retrospective cohort to mitigate random split bias. Logistic regression models using different input combinations were compared, with a model using only clinical factors serving as the baseline. Key predictive features were identified using permutation importance during training. Models were validated by holdout in the prospective cohort to evaluate robustness. Model performance was assessed by the area under the receiver operating characteristic curve (AUROC). RESULTS: Incidence of hs-cTnT elevation was 31.9% in the retrospective and 29.8% in the prospective cohort. The substructure DVH model achieved the highest predictive performance in cross-validation (mean AUROC, 0.71; 95% CI, 0.70-0.73) and demonstrated greater robustness in holdout validation compared with WH-based models (AUROC: 0.60 vs ≤0.51). Feature analysis identified the left anterior descending coronary artery V20Gy as the most dominant predictor, with cutoff values ranging from 0.2% to 5% using various indices. CONCLUSIONS: Cardiac substructure DVH parameters have superior predictive power and robustness over WH variables for predicting hs-cTnT elevation in NSCLC radiation therapy, emphasizing the need to use cardiac substructures for cardiotoxicity risk assessment.
引用
- Chen X, Zhang X, Xu T, et al. Radiation Doses to Cardiac Substructures Predict Elevation in High-sensitivity Cardiac Troponin T Levels in Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41110579. doi:10.1016/j.ijrobp.2025.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。